Equities Analysts Issue Forecasts for CRBP Q1 Earnings

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) – Investment analysts at HC Wainwright issued their Q1 2025 earnings estimates for shares of Corbus Pharmaceuticals in a research report issued on Thursday, November 7th. HC Wainwright analyst A. Maldonado forecasts that the biopharmaceutical company will post earnings per share of ($1.33) for the quarter. HC Wainwright has a “Buy” rating and a $80.00 price target on the stock. The consensus estimate for Corbus Pharmaceuticals’ current full-year earnings is ($3.80) per share. HC Wainwright also issued estimates for Corbus Pharmaceuticals’ Q2 2025 earnings at ($1.40) EPS, Q3 2025 earnings at ($1.46) EPS and Q4 2025 earnings at ($1.54) EPS.

CRBP has been the subject of several other research reports. Royal Bank of Canada restated an “outperform” rating and set a $82.00 target price on shares of Corbus Pharmaceuticals in a research note on Friday, September 20th. Lifesci Capital upgraded shares of Corbus Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, August 21st. B. Riley cut their target price on shares of Corbus Pharmaceuticals from $85.00 to $40.00 and set a “buy” rating for the company in a research note on Friday, September 20th. Mizuho restated an “outperform” rating and issued a $74.00 price target on shares of Corbus Pharmaceuticals in a research report on Friday, September 20th. Finally, Oppenheimer upped their price objective on shares of Corbus Pharmaceuticals from $80.00 to $88.00 and gave the company an “outperform” rating in a research report on Wednesday, August 7th. One equities research analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $65.86.

Corbus Pharmaceuticals Stock Performance

Shares of NASDAQ:CRBP opened at $17.94 on Monday. The stock’s 50-day moving average is $27.47 and its 200-day moving average is $41.83. The company has a market cap of $216.00 million, a P/E ratio of -4.01 and a beta of 2.56. Corbus Pharmaceuticals has a 52-week low of $3.03 and a 52-week high of $61.90.

Institutional Trading of Corbus Pharmaceuticals

Large investors have recently bought and sold shares of the stock. SG Americas Securities LLC bought a new position in shares of Corbus Pharmaceuticals during the third quarter valued at $151,000. Victory Capital Management Inc. increased its position in shares of Corbus Pharmaceuticals by 29.9% during the 3rd quarter. Victory Capital Management Inc. now owns 24,760 shares of the biopharmaceutical company’s stock worth $511,000 after purchasing an additional 5,700 shares in the last quarter. abrdn plc lifted its holdings in Corbus Pharmaceuticals by 422.9% during the 3rd quarter. abrdn plc now owns 26,894 shares of the biopharmaceutical company’s stock valued at $555,000 after purchasing an additional 21,751 shares during the last quarter. Rhumbline Advisers acquired a new position in Corbus Pharmaceuticals in the second quarter valued at about $638,000. Finally, Acadian Asset Management LLC bought a new stake in Corbus Pharmaceuticals during the second quarter worth about $716,000. 64.64% of the stock is currently owned by institutional investors.

Insider Transactions at Corbus Pharmaceuticals

In other Corbus Pharmaceuticals news, major shareholder Cormorant Asset Management, Lp purchased 350,000 shares of the company’s stock in a transaction that occurred on Friday, September 20th. The stock was purchased at an average price of $20.01 per share, with a total value of $7,003,500.00. Following the completion of the transaction, the insider now directly owns 2,375,000 shares of the company’s stock, valued at approximately $47,523,750. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 4.00% of the stock is owned by insiders.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.